Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharmaceuticals limited - glatiramer acetate - pdr+solv for soln for inj - 20 milligram

India - English - Central Drugs Standard Control Organization

natco ph. - glatiramer acetate,mannitol - inj - 20,40;mg - vial

India - English - Central Drugs Standard Control Organization

cipla - glatiramer acetate - inj - 20mg - 1 ml

India - English - Central Drugs Standard Control Organization

intas - glatiramer acetrate,mannitol - inj - 20,40;mg - 2ml

Singapore - English - HSA (Health Sciences Authority)

novartis (singapore) pte ltd - fingolimod hcl 0.56 mg eqv fingolimod - capsule - 0.5mg - fingolimod hcl 0.56 mg eqv fingolimod 0.5mg

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - fingolimod hydrochloride 0.56mg;  ;  ;   - capsule - 0.5 mg - active: fingolimod hydrochloride 0.56mg       excipient: capsugel white 4998 gelatin ink iron oxide yellow magnesium stearate mannitol titanium dioxide - gilenya is indicated as a disease modifying therapy for the treatment of patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: mannitol; iron oxide yellow; magnesium stearate; gelatin; titanium dioxide - fingolimod sandoz is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - fingolimod hydrochloride, quantity: 560 microgram (equivalent: fingolimod, qty 500 microgram) - capsule, hard - excipient ingredients: polacrilin potassium; crospovidone; colloidal anhydrous silica; magnesium stearate; gelatin; sodium lauryl sulfate; titanium dioxide; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - fingolimod sun is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty 0.5 mg) - capsule, hard - excipient ingredients: magnesium stearate; calcium hydrogen phosphate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; iron oxide yellow; titanium dioxide; gelatin - pharmacor fingolimod is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Australia - English - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - fingolimod hydrochloride, quantity: 0.56 mg (equivalent: fingolimod, qty mg) - capsule, hard - excipient ingredients: magnesium stearate; calcium hydrogen phosphate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide; iron oxide yellow; titanium dioxide; gelatin - akm fingolimod is indicated for the treatment of adult and paediatric patients of 10 years of age and above with relapsing forms of multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.